In The News
I’m afraid AI can’t do that: Law firms say smart tech uses limited
Holden dealers reject GM’s bleak alternate reality in class action
Lawyer’s defamation case fails serious harm test, judge finds
Nine, News Corp defeat defamation suits over Central Coast crime coverage
Zip offered Firstmac $4M to settle trade mark suit
High Court rejects Qantas appeal in ground crew sacking case
High Court to rule on reach of workplace law in high-stakes Qantas case
Mosaic Brands boss told GM paying $275K bonus would land him in jail, suit says
ACCC delays decision on Coles acquisition of Saputo plants
Hungry Jack’s to take bite out of franchisee’s profits with ‘competing’ restaurants: suit
Please login to bookmark Close

US pharmaceutical giant Merck Sharp & Dohme has taken a unit of Indian generic manufacturer Lupin to court for allegedly threatening to infringe the patent for its multibillion-dollar diabetes drugs Januvia and Janumet.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
Related articles
Merck Sharp & Dohme slams Wyeth vaccine patent claims as ‘hearsay and speculation’
Allens 2019-02-06 2:44 pm By Miklos Bolza
Merck Sharp & Dohme attacks Wyeth’s ‘broad’ patent claims for Prevnar 13 vaccine
Allens 2018-12-03 2:44 pm By Miklos Bolza
Merck Sharp & Dohme loses key battle in trade mark case ahead of trial
Angela McDonald 2019-07-15 2:44 pm By Miklos Bolza
Wyeth loses privilege claim over Allens docs in Merck’s vaccine patent case
Allens 2019-10-01 2:44 pm By Miklos Bolza
Merck Sharpe & Dohme sues Lupin over Januvia patent
Healthcare 2020-09-07 2:44 pm By Cat Fredenburgh

For information on rights and reprints, contact subscriptions@lawyerly.com.au